HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price target of $6.00 for the company and are expecting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given HTG Molecular Diagnostics an industry rank of 110 out of 265 based on the ratings given to its competitors.

A number of analysts recently weighed in on the stock. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd. HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Wednesday, November 15th.

A number of institutional investors have recently bought and sold shares of the stock. UBS Group AG acquired a new position in HTG Molecular Diagnostics in the 1st quarter worth approximately $137,000. Vanguard Group Inc. boosted its stake in HTG Molecular Diagnostics by 38.9% in the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after purchasing an additional 37,841 shares during the period. Finally, Granahan Investment Management Inc. MA boosted its stake in HTG Molecular Diagnostics by 488.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after purchasing an additional 345,798 shares during the period. 15.45% of the stock is owned by hedge funds and other institutional investors.

HTG Molecular Diagnostics (NASDAQ:HTGM) traded down $0.14 during trading on Friday, hitting $1.89. 424,800 shares of the stock traded hands, compared to its average volume of 1,302,544. HTG Molecular Diagnostics has a twelve month low of $1.20 and a twelve month high of $13.25.

COPYRIGHT VIOLATION NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) Given Consensus Recommendation of “Strong Buy” by Analysts” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-given-consensus-recommendation-of-strong-buy-by-analysts/1745523.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.